Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine
Status:
Terminated
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to determine the efficacy, side effects, and toxicity of an
investigational vaccine that consists of tumor-pulsed dendritic cells administered with an
immune stimulating drug called interleukin-2 (IL-2). Dendritic cells are immune cells that
are obtained from a subject's blood and are important in the body's immune response to
foreign substances. This study will examine the response of a subject's immune system after
receiving several vaccinations containing their own dendritic cells which have been exposed
to dead fragments of their cancer cells in the laboratory. This may result in sensitizing a
subject's dendritic cells to their cancer cells so that their dendritic cells will react with
other cells of the immune system and attack the cancer. It has been shown in the laboratory
that dendritic cells exposed to cancer cell fragments can provide lymphocytes (a type of
white blood cell) with signals they require in order to become fully activated and acquire
the ability to kill cancer cells.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center